The most popular plan in the range More than 10,000 patients No insurance required

Most popular plan

GLP-1 (glucagon-like peptide-1) is an incretin hormone released by cells in your small intestine within minutes of food arriving. It tells the pancreas to release insulin, but only when blood sugar is elevated. It suppresses glucagon, which tells the liver to push stored glucose into the blood. It slows gastric emptying. And it signals satiety to the brain. Natural GLP-1 is destroyed within a couple of minutes, so its effect is a short pulse tied to a meal.

In the brain. Semaglutide binds the same receptor but stays for a week. GLP-1 receptors sit in the hypothalamus and brainstem, which regulate hunger, fullness and reward. Sustained activation lowers the baseline appetite signal. The drop in intrusive thoughts about food is often the first change patients notice.

In the stomach. Food leaves more slowly, so a smaller meal produces fullness that lasts. This is most pronounced after starting or increasing a dose and moderates as the stomach adapts.

In the pancreas. Insulin release in response to a meal improves, and glucagon release is suppressed. Blood sugar after meals is flatter, which reduces the crash-and-crave pattern that drives snacking.

Why it is weekly. Albumin binding gives semaglutide a half-life of roughly seven days, so one dose per week holds a steady blood level. There is no daily peak and trough, which is part of why side effects cluster around dose changes rather than around individual injections.

The figures published in the weight management trials are group averages from randomized studies that included structured lifestyle support. STEP 1 (68 weeks, New England Journal of Medicine, 2021) reported a mean body weight change of approximately negative 14.9% with semaglutide 2.4 mg weekly versus approximately negative 2.4% with placebo. They are not predictions, individual results vary considerably, and Society does not promise any specific amount of weight loss.

This is the standard weight management schedule. Your practitioner may move slower, hold a dose longer, or settle you at a lower dose permanently. Increases happen no more often than every four weeks. There is no clinical prize for reaching the top of the ladder.

Semaglutide is prescription-only in the United States. Anything sold without a clinician review, or as "research use only" peptide, is not a legitimate source. Those vials are not manufactured to pharmaceutical standards, not tested for sterility or dose accuracy, and not intended for human use.

Both are weekly injections that reduce appetite. In the head-to-head trial, tirzepatide produced greater average weight reduction, but semaglutide has the longer real-world track record and a cardiovascular outcomes indication behind its branded product. It is also the lower-cost option in the Society range.

Every figure above is a starting price. Semaglutide starts at $149 a month and what you pay depends on the plan and dose your practitioner prescribes, so treat $149 as the entry point rather than a flat rate across every dose. The price covers the clinician review, your personalized treatment plan, labs, ongoing care and delivery, with no separate consultation fee.

There are no long-term contracts, and you can pause, switch or cancel anytime. Read that alongside the refund policy: the first two (2) months of any treatment plan are strictly non-refundable under any circumstances, and cancelling stops future billing cycles rather than refunding charges already processed.

Questions

Semaglutide from $149 a month, reviewed by a licensed US practitioner, delivered free and discreet in 1 to 2 days.

* Individual results may vary, and not all patients will qualify for treatment. Always consult a licensed healthcare provider before starting or modifying any medical treatment.

Society facilitates access to consultations with independent, licensed healthcare providers who evaluate each patient and determine eligibility for treatment. Prescription products require an online medical evaluation. Medications are prescribed by independent physicians and dispensed by licensed U.S. pharmacies or a patient's preferred pharmacy. Only a qualified healthcare provider can determine whether a treatment is appropriate for an individual's specific medical needs.
Providers are licensed in the state where the patient is located at the time of consultation, and availability may vary by state.
Society's services are intended for individuals 18 years of age or older. Age verification may be required as part of the intake process.
‍Society partners with licensed U.S. pharmacies. Certain treatments may include compounded medications, which are not FDA-approved and have not been evaluated by the Food and Drug Administration for safety, efficacy, or quality. Compounded medications may be prescribed by a healthcare provider based on individual patient needs or during periods of drug shortages. FDA-approved GLP-1 medications—such as Ozempic® (semaglutide), Wegovy® (semaglutide), and Zepbound® (tirzepatide)—are not compounded. Society is not affiliated with, endorsed by, or sponsored by the manufacturers of these products. All trademarks and brand names belong to their respective owners.
GLP-1–based treatments may carry risks, including the potential for thyroid C-cell tumors. These medications should not be used by individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Please consult a healthcare provider for complete prescribing and safety information.
Prescription medications are dispensed only when determined appropriate by a licensed healthcare provider following an online medical evaluation. No prescription is guaranteed, and treatment decisions are made solely at the prescriber's clinical discretion.
Statements on this website have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Images shown are for illustrative purposes only; actual product appearance may vary.